Tag: ALS therapy

FDA, Regulations

FDA declines to review Brainstorm’s ALS therapy

November 11, 2022

Via: Biopharma Dive

The FDA’s choice marks the latest setback for the NurOwn program. When that key, late-stage clinical trial failed in late 2020, Brainstorm’s CEO Chaim Lebovits said the company was confident there would be a path forward for its medicine. Brainstorm […]